Performing knockdown and overexpression assays, we demonstrated that the CASC2 inhibited ESCC cell proliferation, migration and invasion, as well as promoted the sensitivity against cisplatin and capecitabine. Here, CASC2 is linked to esophageal squamous cell carcinoma.